Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo

Autores
Alcazar, Oscar; Achberger, Susan; Aldrich, Wayne; Hu, Zhenbo; Negrotto, Soledad; Saunthararajah, Yogen; Triozzi, Pierre
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Apoptosis genes, such as TP53 and p16/CDKN2A, that mediate responses to cytotoxic chemotherapy, are frequently nonfunctional in melanoma. Differentiation may be an alternative to apoptosis for inducing melanoma cell cycle exit. Epigenetic mechanisms regulate differentiation, and DNA methylation alterations are associated with the abnormal differentiation of melanoma cells. The effects of the deoxycytidine analogue decitabine (5-aza-2'-deoxycytidine), which depletes DNA methyl transferase 1 (DNMT1), on melanoma differentiation were examined. Treatment of human and murine melanoma cells in vitro with concentrations of decitabine that did not cause apoptosis inhibited proliferation accompanied by cellular differentiation. A decrease in promoter methylation, and increase in expression of the melanocyte late-differentiation driver SOX9, was followed by increases in cyclin-dependent kinase inhibitors (CDKN) p27/CDKN1B and p21/CDKN1A that mediate cell cycle exit with differentiation. Effects were independent of the TP53, p16/CDKN2A and also the BRAF status of the melanoma cells. Resistance, when observed, was pharmacologic, characterized by diminished ability of decitabine to deplete DNMT1. Treatment of murine melanoma models in vivo with intermittent, low-dose decitabine, administered sub-cutaneously to limit high peak drug levels that cause cytotoxicity and increase exposure time for DNMT1 depletion, and with tetrahydrouridine to decrease decitabine metabolism and further increase exposure time, inhibited tumor growth and increased molecular and tumor stromal factors implicated in melanocyte differentiation. Modification of decitabine dose, schedule and formulation for differentiation rather than cytotoxic objectives inhibits the growth of melanoma cells in vitro and in vivo. Copyright © 2011 UICC.
Fil: Alcazar, Oscar. Cleveland Clinic Foundation; Estados Unidos
Fil: Achberger, Susan. Cleveland Clinic Foundation; Estados Unidos
Fil: Aldrich, Wayne. Cleveland Clinic Foundation; Estados Unidos
Fil: Hu, Zhenbo. Cleveland Clinic Foundation; Estados Unidos
Fil: Negrotto, Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Cleveland Clinic Foundation; Estados Unidos
Fil: Saunthararajah, Yogen. Cleveland Clinic Foundation; Estados Unidos
Fil: Triozzi, Pierre. Cleveland Clinic Foundation; Estados Unidos
Materia
DECITABINE
DIFFERENTIATION
DNA METHYL TRANSFERASE 1
DNMT1
MELANOMA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/52612

id CONICETDig_5fc10cbe9ce58f285e194aee12e0b31a
oai_identifier_str oai:ri.conicet.gov.ar:11336/52612
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivoAlcazar, OscarAchberger, SusanAldrich, WayneHu, ZhenboNegrotto, SoledadSaunthararajah, YogenTriozzi, PierreDECITABINEDIFFERENTIATIONDNA METHYL TRANSFERASE 1DNMT1MELANOMAhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Apoptosis genes, such as TP53 and p16/CDKN2A, that mediate responses to cytotoxic chemotherapy, are frequently nonfunctional in melanoma. Differentiation may be an alternative to apoptosis for inducing melanoma cell cycle exit. Epigenetic mechanisms regulate differentiation, and DNA methylation alterations are associated with the abnormal differentiation of melanoma cells. The effects of the deoxycytidine analogue decitabine (5-aza-2'-deoxycytidine), which depletes DNA methyl transferase 1 (DNMT1), on melanoma differentiation were examined. Treatment of human and murine melanoma cells in vitro with concentrations of decitabine that did not cause apoptosis inhibited proliferation accompanied by cellular differentiation. A decrease in promoter methylation, and increase in expression of the melanocyte late-differentiation driver SOX9, was followed by increases in cyclin-dependent kinase inhibitors (CDKN) p27/CDKN1B and p21/CDKN1A that mediate cell cycle exit with differentiation. Effects were independent of the TP53, p16/CDKN2A and also the BRAF status of the melanoma cells. Resistance, when observed, was pharmacologic, characterized by diminished ability of decitabine to deplete DNMT1. Treatment of murine melanoma models in vivo with intermittent, low-dose decitabine, administered sub-cutaneously to limit high peak drug levels that cause cytotoxicity and increase exposure time for DNMT1 depletion, and with tetrahydrouridine to decrease decitabine metabolism and further increase exposure time, inhibited tumor growth and increased molecular and tumor stromal factors implicated in melanocyte differentiation. Modification of decitabine dose, schedule and formulation for differentiation rather than cytotoxic objectives inhibits the growth of melanoma cells in vitro and in vivo. Copyright © 2011 UICC.Fil: Alcazar, Oscar. Cleveland Clinic Foundation; Estados UnidosFil: Achberger, Susan. Cleveland Clinic Foundation; Estados UnidosFil: Aldrich, Wayne. Cleveland Clinic Foundation; Estados UnidosFil: Hu, Zhenbo. Cleveland Clinic Foundation; Estados UnidosFil: Negrotto, Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Cleveland Clinic Foundation; Estados UnidosFil: Saunthararajah, Yogen. Cleveland Clinic Foundation; Estados UnidosFil: Triozzi, Pierre. Cleveland Clinic Foundation; Estados UnidosJohn Wiley & Sons Inc2012-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/52612Alcazar, Oscar; Achberger, Susan; Aldrich, Wayne; Hu, Zhenbo; Negrotto, Soledad; et al.; Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo; John Wiley & Sons Inc; International Journal of Cancer. Journal International du Cancer; 131; 1; 7-2012; 18-290020-7136CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1002/ijc.26320info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.26320info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3454528/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:04:43Zoai:ri.conicet.gov.ar:11336/52612instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:04:44.155CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
title Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
spellingShingle Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
Alcazar, Oscar
DECITABINE
DIFFERENTIATION
DNA METHYL TRANSFERASE 1
DNMT1
MELANOMA
title_short Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
title_full Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
title_fullStr Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
title_full_unstemmed Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
title_sort Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
dc.creator.none.fl_str_mv Alcazar, Oscar
Achberger, Susan
Aldrich, Wayne
Hu, Zhenbo
Negrotto, Soledad
Saunthararajah, Yogen
Triozzi, Pierre
author Alcazar, Oscar
author_facet Alcazar, Oscar
Achberger, Susan
Aldrich, Wayne
Hu, Zhenbo
Negrotto, Soledad
Saunthararajah, Yogen
Triozzi, Pierre
author_role author
author2 Achberger, Susan
Aldrich, Wayne
Hu, Zhenbo
Negrotto, Soledad
Saunthararajah, Yogen
Triozzi, Pierre
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv DECITABINE
DIFFERENTIATION
DNA METHYL TRANSFERASE 1
DNMT1
MELANOMA
topic DECITABINE
DIFFERENTIATION
DNA METHYL TRANSFERASE 1
DNMT1
MELANOMA
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Apoptosis genes, such as TP53 and p16/CDKN2A, that mediate responses to cytotoxic chemotherapy, are frequently nonfunctional in melanoma. Differentiation may be an alternative to apoptosis for inducing melanoma cell cycle exit. Epigenetic mechanisms regulate differentiation, and DNA methylation alterations are associated with the abnormal differentiation of melanoma cells. The effects of the deoxycytidine analogue decitabine (5-aza-2'-deoxycytidine), which depletes DNA methyl transferase 1 (DNMT1), on melanoma differentiation were examined. Treatment of human and murine melanoma cells in vitro with concentrations of decitabine that did not cause apoptosis inhibited proliferation accompanied by cellular differentiation. A decrease in promoter methylation, and increase in expression of the melanocyte late-differentiation driver SOX9, was followed by increases in cyclin-dependent kinase inhibitors (CDKN) p27/CDKN1B and p21/CDKN1A that mediate cell cycle exit with differentiation. Effects were independent of the TP53, p16/CDKN2A and also the BRAF status of the melanoma cells. Resistance, when observed, was pharmacologic, characterized by diminished ability of decitabine to deplete DNMT1. Treatment of murine melanoma models in vivo with intermittent, low-dose decitabine, administered sub-cutaneously to limit high peak drug levels that cause cytotoxicity and increase exposure time for DNMT1 depletion, and with tetrahydrouridine to decrease decitabine metabolism and further increase exposure time, inhibited tumor growth and increased molecular and tumor stromal factors implicated in melanocyte differentiation. Modification of decitabine dose, schedule and formulation for differentiation rather than cytotoxic objectives inhibits the growth of melanoma cells in vitro and in vivo. Copyright © 2011 UICC.
Fil: Alcazar, Oscar. Cleveland Clinic Foundation; Estados Unidos
Fil: Achberger, Susan. Cleveland Clinic Foundation; Estados Unidos
Fil: Aldrich, Wayne. Cleveland Clinic Foundation; Estados Unidos
Fil: Hu, Zhenbo. Cleveland Clinic Foundation; Estados Unidos
Fil: Negrotto, Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Cleveland Clinic Foundation; Estados Unidos
Fil: Saunthararajah, Yogen. Cleveland Clinic Foundation; Estados Unidos
Fil: Triozzi, Pierre. Cleveland Clinic Foundation; Estados Unidos
description Apoptosis genes, such as TP53 and p16/CDKN2A, that mediate responses to cytotoxic chemotherapy, are frequently nonfunctional in melanoma. Differentiation may be an alternative to apoptosis for inducing melanoma cell cycle exit. Epigenetic mechanisms regulate differentiation, and DNA methylation alterations are associated with the abnormal differentiation of melanoma cells. The effects of the deoxycytidine analogue decitabine (5-aza-2'-deoxycytidine), which depletes DNA methyl transferase 1 (DNMT1), on melanoma differentiation were examined. Treatment of human and murine melanoma cells in vitro with concentrations of decitabine that did not cause apoptosis inhibited proliferation accompanied by cellular differentiation. A decrease in promoter methylation, and increase in expression of the melanocyte late-differentiation driver SOX9, was followed by increases in cyclin-dependent kinase inhibitors (CDKN) p27/CDKN1B and p21/CDKN1A that mediate cell cycle exit with differentiation. Effects were independent of the TP53, p16/CDKN2A and also the BRAF status of the melanoma cells. Resistance, when observed, was pharmacologic, characterized by diminished ability of decitabine to deplete DNMT1. Treatment of murine melanoma models in vivo with intermittent, low-dose decitabine, administered sub-cutaneously to limit high peak drug levels that cause cytotoxicity and increase exposure time for DNMT1 depletion, and with tetrahydrouridine to decrease decitabine metabolism and further increase exposure time, inhibited tumor growth and increased molecular and tumor stromal factors implicated in melanocyte differentiation. Modification of decitabine dose, schedule and formulation for differentiation rather than cytotoxic objectives inhibits the growth of melanoma cells in vitro and in vivo. Copyright © 2011 UICC.
publishDate 2012
dc.date.none.fl_str_mv 2012-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/52612
Alcazar, Oscar; Achberger, Susan; Aldrich, Wayne; Hu, Zhenbo; Negrotto, Soledad; et al.; Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo; John Wiley & Sons Inc; International Journal of Cancer. Journal International du Cancer; 131; 1; 7-2012; 18-29
0020-7136
CONICET Digital
CONICET
url http://hdl.handle.net/11336/52612
identifier_str_mv Alcazar, Oscar; Achberger, Susan; Aldrich, Wayne; Hu, Zhenbo; Negrotto, Soledad; et al.; Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo; John Wiley & Sons Inc; International Journal of Cancer. Journal International du Cancer; 131; 1; 7-2012; 18-29
0020-7136
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1002/ijc.26320
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.26320
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3454528/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv John Wiley & Sons Inc
publisher.none.fl_str_mv John Wiley & Sons Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613875529416704
score 13.070432